Evidence map›Paper›PMID 34054292›Full record

ArticlePatient preference and adherence2021

Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.

M Janelle Cambron-Mellott, Jaromir Mikl, Joana E Matos, Jennifer G Erensen, Kathleen Beusterien, Marc J Cataldo, Bernadette Hallissey, Gregory W Mattingly

Open access · goldAbstract read
In one paragraph

Article in Patient preference and adherence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

M Janelle Cambron-MellottKantar Health, New York, NY, USA.ORCID 0000-0003-0061-104X
Jaromir MiklPurdue Pharma L.P./Adlon Therapeutics, L.P., Stamford, CT, USA.ORCID 0000-0002-5658-9809
Joana E MatosKantar Health, New York, NY, USA.ORCID 0000-0003-0768-6765
Jennifer G ErensenPurdue Pharma L.P./Adlon Therapeutics, L.P., Stamford, CT, USA.ORCID 0000-0003-0259-7122
Kathleen BeusterienKantar Health, New York, NY, USA.ORCID 0000-0001-7786-5422
Marc J CataldoPurdue Pharma L.P./Adlon Therapeutics, L.P., Stamford, CT, USA.ORCID 0000-0003-1918-8130
Bernadette HallisseyKantar Health, New York, NY, USA.ORCID 0000-0001-9910-2143
Gregory W MattinglyDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-0234-6860
Kantar Health (United States) · USPurdue Pharma (United States) · USPolitical Research Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveTreatment for attention deficit hyperactivity disorder (ADHD) requires a multifaceted approach including psychosocial interventions and pharmacological treatment. This study evaluates preferences for specific attributes associated with different long-acting stimulant treatment among US adults with ADHD.

methodsPatients completed an online, cross-sectional survey, incorporating a discrete choice experiment to assess preferences for attributes.

resultsAnalyses included 200 adults with ADHD (mean age 33.0 years; 60% self-reporting moderate severity); the mean (SD) Adult ADHD Self-Report Scale-v1.1 score was 45.9 (12.4). Overall, patients valued speed of onset most and risk of rebound least. Three population groups with distinct preferences were identified: side effect-driven (n=69, 35%), quick onset-driven (n=47, 24%) and quick onset and long duration-driven (n=84, 42%).

conclusionThis study shows differences in how adults with ADHD value and assess benefit-risk trade-offs when considering the desired attributes of stimulant treatments, highlighting the importance of patient-physician shared decision-making to optimize the desired benefits of individualized treatment.

Indexed as

attention deficit hyperactivity disorderchoice behaviorCNS stimulantsdiscrete choice experimentpatient preference

Identifiers

PMID34054292
PMCPMC8158042
OpenAlexW3161818799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.